SUMMIT (dpa-AFX) - Celgene International Sàrl, a wholly owned subsidiary of Celgene Corp. (CELG), Sunday reported results from its phase II investigator initiated study of Revlimid in combination with Avastin, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer or mCRPC.
Study reports that 86.4 percent of patients enrolled achieved 50 percent reduction of Prostate-specific antigen (PSA) or better. More than 70 percent of the patients on the trial had a reduction in PSA of at least 75 percent.
In the study, patients with chemotherapy naive, progressive mCRPC were treated with docetaxel and bevacizumab on day one, plus lenalidomide on days 1-14, with daily prednisone and enoxaparin during each 21-day cycle.
Revlimid or lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
Copyright RTT News/dpa-AFX